Eli Lilly and Company (NYSE:LLY - Get Free Report) traded down 1.4% during trading on Thursday . The stock traded as low as $774.95 and last traded at $776.33. 627,685 shares traded hands during trading, a decline of 79% from the average session volume of 3,008,952 shares. The stock had previously closed at $787.02.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a "buy" rating in a research report on Tuesday. Barclays increased their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 7th. Citigroup upped their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a "buy" rating in a report on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Finally, Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $769.53.
Get Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Stock Performance
The business has a fifty day moving average of $760.67 and a 200-day moving average of $682.27. The company has a market cap of $732.88 billion, a PE ratio of 114.33, a P/E/G ratio of 1.50 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm's revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.62 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.
Eli Lilly and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be given a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.67%. Eli Lilly and Company's dividend payout ratio is presently 76.58%.
Institutional Trading of Eli Lilly and Company
A number of hedge funds have recently made changes to their positions in the stock. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Tidemark LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company's stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth $37,000. 82.53% of the stock is owned by institutional investors.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
